Akèy › Kansè poumon › Utah › Salt Lake City
Etid klinik pou Kansè poumon nan Salt Lake City, UT
21 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Salt Lake City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- University of Utah, Salt Lake City
- Veterans Affairs SLC Health Care System (VAMC), Salt Lake City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Ap rekriteFaz 3
- Huntsman Cancer Institute ( Site 0042), Salt Lake City
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Ap rekriteFaz 2/3
- Huntsman Cancer Institute, Salt Lake City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- Utah Cancer Specialists, Salt Lake City
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- Huntsman Cancer Institute, Salt Lake City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics
Ap rekriteVolontè an sante akeyi
- Huntsman Cancer Institute/ University of Utah, Salt Lake City
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Ap rekriteFaz 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Huntsman Cancer Institute, Salt Lake City
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Ap rekriteFaz 1/2
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Huntsman Cancer Institute, Salt Lake City
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- University of Utah, Huntsman Cancer Institute, Salt Lake City
Improving Care for Rural Patients With Solid Tumors
Ap rekrite
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- Utah Cancer Specialists (site 203), Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Salt Lake City
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Arlington, VA41 etid
- Washington, DC41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan Salt Lake City
- Kansè Poumon ki pa ti selil31 etid
- Kansè (tout kalite)27 etid
- Kansè nan tete27 etid
- Kansè kolorektal22 etid
- Melanom21 etid
- Myelom Miltip21 etid
- Kansè Metastatik20 etid
- Kansè ovè19 etid
- Obèsite18 etid
- Leksemi mieloïd egi17 etid
- Ensifizyans kadyak17 etid
- Kansè pwostat15 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.